The Incurable Files · No. 1 Multiple Sclerosis · Myelin · Terrain By Jasper Vermeer · 24 July 2026
🇳🇱 Lees in het Nederlands

Multiple Sclerosis: The Fixed Sentence

Here is the sentence most people with multiple sclerosis are handed, in substance if not in exact words: this is permanent, it will likely get slowly worse, and the medication you take from now on is designed to slow that decline, not reverse it. That framing is treated as a simple restatement of biological fact. It isn't. It's one reasonable reading of an evidence base that also contains a 32-fold risk finding published in 2022 that rewrites what MS actually is, a documented biological repair system that keeps getting suppressed rather than absent, and at least one real clinical trial where disability went down, not just slower up. None of that is fringe. All of it is published, peer-reviewed, and largely absent from what patients hear in the room where the sentence gets handed down.

32× Higher MS risk after Epstein-Barr infection[1]
6–10 yrs Life expectancy gap vs. general population[15]
40% Patients initially misdiagnosed before MS confirmed[7]

What Actually Causes This

Multiple sclerosis is what happens when the immune system — T cells first, B cells now understood to matter just as much — attacks the myelin sheath insulating nerve fibers in the brain and spinal cord. The name is literally descriptive: sclerosis means scarring, and MS is the accumulation of scar tissue where myelin used to be. A demyelinated nerve doesn't transmit signal cleanly. It slows, it degrades, it sometimes fails outright. That's the disease, mechanically.

What causes the immune system to turn on its own insulation was, until recently, genuinely unclear — a mix of genetic predisposition (HLA-DRB1*15:01 remains the strongest single genetic marker, roughly tripling risk[3]) and a loose cloud of environmental risk factors: low vitamin D, smoking, obesity, and latitude. Then, in January 2022, a study in Science changed the picture.

The EBV Finding — Not Correlation, Causation-Grade Evidence

Researchers followed over 10 million US military personnel for 20 years, with blood samples banked throughout. 955 of them developed MS. The finding: risk of MS increased 32-fold after Epstein-Barr virus infection — and did not increase after infection with other viruses, including cytomegalovirus, a similarly-transmitted herpesvirus used as a control. Blood biomarkers of nerve damage only began rising after the EBV infection itself, not before. In the authors' own words, this "cannot be explained by any known risk factor for MS."

A follow-up mechanistic study found the reason: roughly a quarter of MS patients carry antibodies that cross-react between an EBV protein (EBNA1) and a protein in the central nervous system (GlialCAM) — the immune system, trained to fight EBV, mistakes brain tissue for the virus. This is molecular mimicry, demonstrated structurally, not inferred.[2]

The honest caveat: EBV infects roughly 95% of adults, and only a small fraction develop MS. EBV appears necessary, not sufficient — it needs the genetic and environmental co-factors above to actually produce the disease. But "necessary" is still a category shift. This isn't a disease that arrives for no reason. It has a trigger, and the trigger is identifiable.

Bjornevik et al. (2022) — Science 375(6578):296-301, PMID 35025605 · Lanz et al. (2022) — Nature 603:321-327, EBNA1/GlialCAM cross-reactivity.

The part of this story that matters most for what comes later in this article is what happens to the myelin itself once it's damaged. The standard framing is that the damage is simply permanent. The actual literature is more specific than that.

Repair Capacity Exists — and Is Actively Blocked

MS lesions contain living oligodendrocyte precursor cells — the cells that build new myelin — in substantial numbers, and they are capable of maturing into myelin-producing cells. Early, partial remyelination inside lesions is well documented (pathologists call the result "shadow plaques"). This is not a fringe finding; it's established neuroimmunology.

What prevents full repair is a specific, named set of blockers: molecular inhibitors on the cell surface (LINGO-1 among them), chronic inflammation that — past a certain point — stops supporting repair and starts suppressing it, and age-related declines in the precursor cells' ability to differentiate.

The distinction matters. "Your myelin can't come back" and "your myelin's repair system is present but actively suppressed by ongoing inflammation" are different diagnoses with different implications. The second one is what the evidence actually supports.[4]

Gruchot et al. (2019) — Cells 8(8):825, "The Molecular Basis for Remyelination Failure in Multiple Sclerosis," PMC6721708.

How You Get the Diagnosis

The current diagnostic standard is the McDonald criteria, last revised in 2017: MRI evidence of lesions in at least two of four (now five) characteristic locations, appearing at different points in time, sometimes substituted for by spinal fluid analysis.[5] A further revision was published in 2025 — barely months before this article — that eases the "different points in time" requirement, meaning diagnosis can now happen faster in some patients than it could a year ago.[6]

Getting there is rarely fast. A 2025 registry study of 428 MS patients found 40.4% had their eventual MS symptoms initially misattributed to something else, with a mean delay of nearly two years before correct diagnosis.[7] The disease itself is classified into relapsing-remitting, secondary progressive, and primary progressive forms — note: the older four-category system including a separate "progressive-relapsing" category was retired in 2014 in favor of a two-axis model (activity vs. progression), so if you see the old terminology in older material, it's out of date.[8]

What You're Told to Do About It

Disease-modifying therapies — interferons, fingolimod, ocrelizumab, and a dozen others — work by suppressing or redirecting immune activity. None of them are designed to regenerate myelin, and none currently do.[9] That much is uncontroversial and worth stating plainly, because it's the actual mechanical basis of the "manage decline, don't reverse it" framing: these drugs were never built to reverse anything. They were built to slow the rate of new damage.

What's genuinely debated — and rarely presented as debated — is how well they succeed even at that. Do they just reduce relapses, or do they meaningfully slow the accumulation of permanent disability?

The Disability-Progression Question — Reported Honestly, Both Ways

A 2019 overview of 22 separate meta-analyses on DMTs found solid evidence for reducing relapse frequency, but results on long-term disability progression "varied substantially between meta-analyses," with "little evidence of efficacy... over longer periods." A 2024 Cochrane network meta-analysis of DMTs in progressive MS found only low or very low certainty evidence for disability benefit — not proof of no effect, but a genuine gap in confidence.[10]

Against that: the ORATORIO trial found ocrelizumab reduced confirmed disability progression at 24 weeks from 35.7% to 29.6% in primary progressive MS (p=0.04) — a real, statistically significant, positive result. Its sister trials in relapsing MS (OPERA I/II) found a similar pattern.[11]

The honest synthesis: the claim "DMTs only slow relapses and do nothing for real disability" is an overstatement contradicted by real trial data. The claim "DMTs solve disability progression" is also not supported — the evidence is inconsistent across drugs, populations, and how long you follow patients, and no drug in this class reverses damage that's already occurred. Both oversimplifications are wrong in the same direction: toward more certainty than the data has.

Claflin et al. (2019) — Frontiers in Neurology 9:1150, PMC6335290 · Cochrane 2024, CD015443 · Montalban et al. (2017) — NEJM 376:209-220 (ORATORIO), PMID 28002688 · Hauser et al. (2017) — NEJM 376:221-234 (OPERA I/II).

Here's what's harder to find a citation for, and more revealing for that reason: what patients are actually told. The NHS's own patient-facing material states it plainly: "There is currently no cure for multiple sclerosis (MS). But there are treatments that can slow the progression of MS and help ease symptoms." Never "reverse." Never "restore." That's not a doctor being blunt in an exam room — it's the literature itself, structurally built around deceleration as the ceiling of what's offered.[12] And in a strange twist, research on doctor-patient communication suggests even that much often doesn't get said aloud: one study found 68.5% of MS patients had never had a detailed conversation with their neurologist about long-term prognosis at all, though most wanted to.[13] The ceiling isn't usually stated as a sentence. It's built into the paperwork and rarely discussed directly.

What They Don't Usually Mention

If the standard treatment paradigm is built around slowing decline, the natural question is whether anything has been shown, in a real trial, to do better than that. The honest answer is: rarely, but yes — and the clearest case is not a botanical protocol. It's a stem cell transplant.

HSCT — The Trial Where Disability Went Down

The MIST randomized trial compared hematopoietic stem cell transplantation (a chemotherapy-based immune system reset) against continued standard DMT therapy in relapsing-remitting MS. At one year, the disability score (EDSS) in the transplant group improved — from 3.38 to 2.36. The DMT comparison group got worse, from 3.31 to 3.98. Disease progression occurred in 3 of 50 HSCT patients versus 34 of 51 on standard therapy.[16]

This is real improvement, not just a slower decline — a meaningfully different outcome than anything in the DMT literature above. It comes with real caveats the trial's own authors flagged: small sample, open-label design, and a procedure that carries genuine transplant-related risk. A separate long-term follow-up study found the treatment works best when used early in active relapsing disease — not, as current practice usually sequences it, as a last resort after other treatments have already failed.[17]

This isn't an argument that a botanical protocol achieves what HSCT achieves — it doesn't, and claiming otherwise would be dishonest. It's evidence that "improvement is biologically impossible" is simply false as a general statement about this disease, which is the point the standard framing quietly assumes.

Burt et al. (2019) — JAMA 321(2):165-174, PMID 30644982 · Muraro et al. (2017) — JAMA Neurology 74(4):459-469, PMID 28241268.

Two other data points worth knowing, reported at the strength they actually deserve: a randomized dietary trial (the Wahls-vs-Swank WAVES study) found real, measured improvements in fatigue and quality of life from diet alone — not disability reversal, but a real, RCT-confirmed benefit that most patients are never told is available.[18] Vitamin D, despite its popularity, has genuinely mixed trial evidence for relapse reduction and none for disability — worth taking for general health, not oversold as an MS treatment.[19]

The Terrain Argument

Put the pieces together and a different model of the disease emerges — not a replacement for the immunological one, but a more complete version of it. Inflammation attacks myelin. That attack leaves scar tissue and exposed, poorly-insulated nerve fiber — the biological version of a short circuit. The repair machinery for this exists and is biologically active, but it is being outcompeted by the very inflammation causing the damage in the first place. Standard treatment addresses the inflammation with immune suppression — genuinely useful, given the EAE/cuprizone-model and clinical trial evidence below — but stops there. It rarely also supplies the specific signal that tells the repair machinery where to work, and almost never protects the one biological window in which the brain's own cleanup and repair system is active at all: sleep.

That three-part gap — inflammation control, targeted repair signal, and protected repair time — is what the rest of this protocol is built around. Not a replacement for medical treatment. The part of the picture medical treatment doesn't currently address.

The Protocol — Built From the Gap, Not Around It

Putting Out the Fire — Turmeric, Ceylon Cinnamon, Boswellia

Turmeric's anti-inflammatory profile is one of the best-documented in botanical medicine — real reductions in CRP, IL-6 and TNF-α across meta-analyses, and real pain/function benefit in osteoarthritis trials. More specific to this disease: curcumin has suppressed clinical disease and preserved myelin in the standard animal model of MS (EAE) and in a separate cuprizone demyelination model — one study explicitly reported "restored... myelination" in treated mice. Ceylon cinnamon has an almost identical result in the same EAE model, working through regulatory T-cell induction. Boswellia serrata carries the strongest human evidence in this entire stack for MS specifically: a double-blind randomized trial in 60 MS patients found measurable cognitive improvement over eight weeks.

Black pepper's piperine boosts turmeric's famously poor bloodstream absorption — real mechanism, though the often-cited "2,000% increase" figure comes from one small 1998 study that's never been independently replicated at that scale.

Cho et al. (2009) — Int Immunopharmacol, PMID 19539560 · Al-Amin et al. (2022) — Int J Mol Sci 23(15):8407, PMID 35955792 · Mondal & Pahan (2015) — PLOS ONE, PMID 25569428 · Majdinasab et al. (2016) — J Herbal Medicine 6(3):119-127 · Shoba et al. (1998) — Planta Medica 64(4):353-356.

Rebuilding the Insulation — Lion's Mane, Specifically

Of everything in this protocol, Lion's Mane (Hericium erinaceus) is the one ingredient with evidence pointing at the repair step itself, not just the inflammation around it. It induces nerve growth factor (NGF) production — shown directly in human astrocytoma cells — and, in a 2021 study, promoted oligodendrocyte maturation with a measured increase in myelin basic protein, the structural protein of myelin itself. A separate small (n=30) human trial found cognitive improvement in adults with mild cognitive impairment over 16 weeks.

This is the ingredient doing a functionally different job than the anti-inflammatories above — which is why it's treated as a separate step in the protocol, not folded into the "calm the immune system down" category.

Mori et al. (2009) — Phytother Res 23(3):367-372, PMID 18844328 · Kolotushkina et al. (2021) — Scientific Reports, PMID 33753806 · In-vitro NGF induction, PMID 18758067.
Daytime priming — Ginkgo, Rosemary, Gotu Kola, Sage Circulation and BBB support, taken before the active evening phase Ginkgo is traditionally used for cerebral micro-circulation; Rosemary's carnosic acid has documented blood-brain-barrier protective activity; Gotu Kola's best-proven human uses are wound healing and venous circulation, with BDNF support so far shown only in animals, not humans. Ginkgo also raises bleeding risk with blood thinners — see cautions below.
Brahmi (Bacopa monnieri) — cognitive support A separate evidence base from the myelin question One of the better-replicated nootropic herbs: meta-analyzed cognitive benefit with 12+ weeks of use, plus real anxiolytic trial data. No demyelination-specific evidence — it belongs in the "support the person" category, not the "repair the tissue" category.
Kinetic activation — balance work immediately after intake Proven in mice, indirectly supported in humans The damaged circuit already exists; that's the disease. Activating it through balance exercise is what tells the repair system which pathway needs work — directly demonstrated via optogenetic activation in mice,[20] with supporting (imaging-based, not cellular) evidence from human motor-learning studies.
The nightly glymphatic window Proven in mice, indirect but real in humans The brain has no conventional lymphatic system — it clears metabolic waste through the glymphatic system instead, which activates during deep sleep and was measured (in mice) to expand brain interstitial space by ~60%.[21] Darkness and cold both support the mechanisms that trigger this. Downstream, that fluid does drain through real lymphatic vessels in the meninges,[22] but we found no direct evidence that posture specifically affects this drainage, so we're not claiming it does.

Before You Start

This is a complement to treatment, not a replacement. The disability-progression evidence above is genuinely mixed, not zero — real trials show real benefit for some DMTs. Never stop, reduce, or delay prescribed medication because of this article without talking to your neurologist.

Piperine and curcumin both inhibit CYP3A4, a liver enzyme pathway shared by a large share of prescription drugs — including siponimod, most statins, and many immunosuppressants. This is the same mechanism that makes grapefruit dangerous with certain medications. Check with your doctor or pharmacist if you take anything regularly, and skip the grapefruit.[25]

Ginkgo raises bleeding risk with blood thinners and antiplatelet drugs — confirmed in real-world outcome data, not theoretical.[24]

Alcohol works against this protocol's own logic: it fragments the deep sleep the nightly glymphatic step depends on, and at higher doses has been shown to directly suppress glymphatic clearance itself.[23]

Ginkgo/anticoagulants: PMID 26958257 · Piperine/CYP3A4 modeling: PMID 39456737 · Alcohol/glymphatic system: Lundgaard et al. (2018), Scientific Reports, PMID 29396480.

The Sovereign Position

"Incurable" is doing more work in that sentence than the evidence supports. What's actually true: the specific drugs currently approved for MS were built to suppress immune activity, not repair tissue, and they do that job with real but inconsistent success. What's also true, and almost never placed next to the first fact: the repair machinery for myelin exists in the tissue itself, gets actively blocked by the same inflammation the drugs are fighting, and at least one aggressive intervention has produced actual, measured improvement rather than slowed decline — in a real randomized trial, not a testimonial.

None of that makes MS simple, and none of it licenses throwing out disease-modifying therapy for a tea and a balance exercise. It does mean the sentence handed down at diagnosis — decline, managed — is a description of what the standard toolkit is built to do, not a ceiling written into your biology. Fight the inflammation. Feed the one repair signal that's actually been shown to matter. Protect the sleep window where any of this can happen at all. That's a different instruction than "accept it," and it's the one the full evidence base actually supports.

The diagnosis is real. The verdict isn't automatic.

MS involves real, autoimmune-driven damage to real tissue — nothing here disputes that. But "incurable" has quietly come to mean "nothing can improve," and that's a claim the literature doesn't make. Myelin repair capacity exists and is suppressed, not absent. At least one real trial has shown disability go down instead of up. The standard treatment paradigm targets one part of a three-part problem. Knowing where the other two parts are is not false hope — it's just reading the rest of the paper.

The full protocol referenced above, with dosing and application detail.

The Insulation Restoration Protocol → Architecture of Disease →

Sources

  1. Bjornevik K, Cortese M, Healy BC, et al. "Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis." Science. 2022;375(6578):296-301. PMID 35025605
  2. Lanz TV, Brewer RC, Ho PP, et al. "Clonally expanded B cells in multiple sclerosis bind EBV EBNA1 and GlialCAM." Nature. 2022;603:321-327.
  3. Patsopoulos NA, et al. "DNA methylation as a mediator of HLA-DRB1*15:01 and a protective variant in multiple sclerosis." Nat Commun. 2018. PMC6008330
  4. Gruchot J, Weyers V, Göttle P, et al. "The Molecular Basis for Remyelination Failure in Multiple Sclerosis." Cells. 2019;8(8):825. PMC6721708
  5. Thompson AJ, Banwell BL, Barkhof F, et al. "Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria." Lancet Neurol. 2018;17(2):162-173. PMID 29275977
  6. Montalban X, Lebrun-Frenay C, Oh J, et al. "Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteria." Lancet Neurol. 2025;24(10):850-865.
  7. "Diagnostic delay and misdiagnosis in multiple sclerosis." 2025 registry study. PMC12033781
  8. Lublin FD, Reingold SC, Cohen JA, et al. "Defining the clinical course of multiple sclerosis: the 2013 revisions." Neurology. 2014;83(3):278-286. PMID 24871874
  9. "Multiple Sclerosis: Immunopathology and Treatment Update." PMC5532591
  10. Claflin SB, Broadley S, Taylor BV. "Disease modifying therapies for multiple sclerosis: benefit and acceptability." Front Neurol. 2019;9:1150. PMC6335290
  11. Montalban X, Hemmer B, Rammohan K, et al. (ORATORIO) NEJM. 2017;376:209-220. PMID 28002688 · Hauser SL, et al. (OPERA I/II) NEJM. 2017;376:221-234.
  12. NHS. "Multiple sclerosis — Treatment." nhs.uk
  13. "How Do People with Multiple Sclerosis Experience Prognostic Uncertainty and Prognosis Communication?" PLOS ONE.
  14. Norwegian 60-year cohort (Hordaland County) and Finnish nationwide register mortality study. PMC12048406
  15. Burt RK, Balabanov R, Burman J, et al. "Effect of Nonmyeloablative HSCT vs Continued DMT on Disease Progression in RRMS: A Randomized Clinical Trial." JAMA. 2019;321(2):165-174. PMID 30644982
  16. Muraro PA, Pasquini M, Atkins HL, et al. "Long-term Outcomes After Autologous HSCT for Multiple Sclerosis." JAMA Neurol. 2017;74(4):459-469. PMID 28241268
  17. Wahls TL, Titcomb TJ, Bisht B, et al. "Impact of the Swank and Wahls elimination dietary interventions... WAVES randomized parallel-arm clinical trial." Mult Scler J Exp Transl Clin. 2021. PMC8326636
  18. EVIDIMS trial, vitamin D3 dosing in MS. PMID 32047645
  19. Gibson EM, Purger D, Mount CW, et al. "Neuronal activity promotes oligodendrogenesis and adaptive myelination in the mammalian brain." Science. 2014;344(6183):1252304. PMID 24727982
  20. Xie L, Kang H, Xu Q, et al. "Sleep Drives Metabolite Clearance from the Adult Brain." Science. 2013;342(6156):373-377.
  21. Louveau A, Smirnov I, Keyes TJ, et al. "Structural and functional features of central nervous system lymphatic vessels." Nature. 2015;523:337-341.
  22. Lundgaard I, Wang W, Eberhardt A, et al. "Beneficial effects of low alcohol exposure, but adverse effects of high alcohol intake, on glymphatic function." Sci Rep. 2018;8:2246. PMID 29396480
  23. Ginkgo/anticoagulant bleeding risk, VA population study. PMID 26958257
  24. Lin F, et al. "Predicting Food–Drug Interactions between Piperine and CYP3A4 Substrate Drugs Using PBPK Modeling." Int J Mol Sci. 2024;25(20):10955. PMID 39456737

The Reference

500 botanicals — each with documented mechanisms, dosages, and synergy protocols. The complete reference for sovereign health practice.

The 500 Most Powerful Botanicals →